Baricitinib Versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to Background Methotrexate (MTX) Therapy: Results of a 52-Week Phase 3 Study

Background: In phase 3 studies, baricitinib improved disease activity in patients with active RA and an inadequate response (IR) to DMARDs. We report results from a 52-week study of baricitinib in MTX-IR RA patients. Methods: Patients with active RA (TJC≥6 & SJC≥6 & hsCRP≥6mg/L)[for full text, please go to the a.m. URL]
44. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 30. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 26. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)